Connect with us

Medical Devices

Insulet’s Omnipod® 5 Automated Insulin Delivery System Improves Clinical Outcomes in Type 1 Diabetes

Avatar

Published

on

ACTON, Mass.–(BUSINESS WIRE)– Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced positive results from the first pivotal trial for the Omnipod® 5 Automated Insulin Delivery System. Omnipod 5, the world’s first tubeless, wearable system that continuously adapts insulin delivery based on glucose levels and trends, significantly improved time in range and reduced HbA1c in children, adolescents, and adults, aged 6-70 years, with type 1 diabetes. The data was presented at ENDO 2021, the Endocrine Society’s annual meeting and a leading forum for endocrinology research and clinical care worldwide.

“Our team has been committed to developing a hybrid closed-loop insulin delivery system to advance the treatment of insulin-dependent diabetes,” said Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director. “Our pivotal study has achieved remarkable improvement in glucose control, evidenced by impressive reduction in HbA1c and improved time in range, together with the lowest rates of hypoglycemia. We are incredibly proud of these results, which demonstrate the system is safe and effective across a wide range of age groups. This is another step forward in our mission to simplify life for people with diabetes.”

Omnipod 5 System Pivotal Study Overview

Insulet presented its data in two groups of type 1 diabetes patients: 128 adults and adolescents between 14 and 70 years old, and 112 children age 6 to 13.9 years. The participants used the Omnipod 5 System at home for a period of 3 months after a 14-day period using their standard therapy, which included both pump therapy and multiple daily injections.

The Omnipod 5 System showed a significant increase in time in range (70-180 mg/dL) in the adults and adolescents, from 65% to 74%, or an additional 2.2 hours per day, and an overall reduction of HbA1c from 7.16% to 6.78%. Participants also saw a decrease in mean glucose from 161 to 154 mg/dL. Median time below 70 mg/dL improved from 2.0 to 1.1%. At a target glucose of 110 mg/dL, subjects achieved 76% time in range.

In children, time in range improved from 53% to 68%, corresponding to an additional 3.7 hours per day in target range. Additionally, HbA1c improved from 7.67% to 6.99% and the mean glucose level decreased from 183 to 160 mg/dL. Median time below 70 mg/dL stayed remarkably low at 1.5%.

“The daily management of type 1 diabetes is relentless,” said Jose S., father of a pediatric pivotal trial participant. “Caregivers make multiple decisions each day that profoundly affect their loved one’s wellness and safety. Insulet’s Omnipod 5 System reduces this burden by automating much of the decision making. It also provided me peace of mind by mitigating the threat of hypoglycemia.”

Assistant Professor Gregory Forlenza at Barbara Davis Center, University of Colorado and Principal Investigator agreed that Omnipod 5 makes diabetes management simpler, while improving overall clinical results for users.

“The Omnipod 5 System is phenomenal, improving diabetes outcomes for children and adults while greatly reducing the burden of diabetes management,” said Dr. Forlenza. “With the algorithm built into the Pod itself, it is easier than ever for people with diabetes to rely on automated insulin delivery to manage their blood glucose levels and keep them in range. Insulet has created a very impressive device that will surely change lives.”

Nearly all participants completed the pivotal study (98% of all participants) and virtually all of those opted to continue using the Omnipod 5 System during an extension phase of the study. The study results and participants’ desire to continue with the extension phase demonstrates their overall satisfaction with the Omnipod 5 System.

“It was remarkable how quickly every family learned to trust the automation, allowing people to sleep through the night for the first time in years,” said Professor Irl Hirsch, University of Washington. “The significant improvement in glycemic outcomes they achieved with the use of Omnipod 5, including the remarkably low rates of hypoglycemia, led to a tremendous reduction in the burden of care for so many.”

The Omnipod 5 System received breakthrough device designation from the U.S. Food and Drug Administration and is currently under review. The Company expects to launch Omnipod 5 in limited release during the first half of 2021.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: www.insulet.com and www.omnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet’s expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission in February 2021 in the section entitled “Risk Factors,” and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

©2021 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210320005001/en/

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.biospace.com/article/releases/insulet-s-omnipod-5-automated-insulin-delivery-system-improves-clinical-outcomes-in-type-1-diabetes/?s=93

Medical Devices

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

Avatar

Published

on

UltraSight (formerly OnSight Medical), a Digital Health pioneer for cardiac imaging and beyond, announced today that it has closed a $13 million Series B funding round.

The investment will be used to advance U.S. clinical programs for its real time, AI guidance in a variety of care settings. The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

UltraSight’s AI platform provides the engine for ultrasound devices to conduct sonography at the point of care, helping more patients be accurately diagnosed and treated.  Point of care ultrasound allows medical professionals to diagnose patients wherever they are including clinics, community hospitals, ambulances and remote settings. Currently, cardiac sonography is a skill that takes years to acquire and requires daily practice to maintain high proficiency, creating a shortage in these highly specialized professionals. UltraSight aims to change this dynamic by offering clinicians with no prior sonography training, automated guidance and quality assessment, for conducting ultrasound scans.

UltraSight also announced the strengthening of its medical and scientific advisory board with the appointment of Al Lojewski, former General Manager Cardiology Solutions at GE Healthcare, Laurance Grossman, MD, Radiologist at Cleveland Clinic, and Andrew Cleeland, CEO of Fogarty Innovation.

“We see a future where ultrasound is readily available to assess any patient, anywhere and by any healthcare professional. Simplifying ultrasound is critical to providing fast, effective care,” said Andrew Cleeland, CEO of Fogarty Innovation. “By making ultrasound ubiquitous, UltraSight has the potential to bring the benefits of cardiac imaging to more healthcare professionals and new care settings.”

“UltraSight provides a novel and versatile platform that addresses the unmet needs of patients and physicians,” said Davidi Vortman, CEO of UltraSight. “This financing round places us on the path to become a leading player in the ultrasound industry.”

“We are excited to help realize UltraSight’s mission,” said Wonjae Lee, Head of Asia Pacific, The Yozma Group. “UltraSight’s innovation is poised to reshape the ultrasound market and propel market growth.”

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/ultrasight-raises-13-million/

Continue Reading

Medical Devices

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

Avatar

Published

on

UltraSight (formerly OnSight Medical), a Digital Health pioneer for cardiac imaging and beyond, announced today that it has closed a $13 million Series B funding round.

The investment will be used to advance U.S. clinical programs for its real time, AI guidance in a variety of care settings. The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

UltraSight’s AI platform provides the engine for ultrasound devices to conduct sonography at the point of care, helping more patients be accurately diagnosed and treated.  Point of care ultrasound allows medical professionals to diagnose patients wherever they are including clinics, community hospitals, ambulances and remote settings. Currently, cardiac sonography is a skill that takes years to acquire and requires daily practice to maintain high proficiency, creating a shortage in these highly specialized professionals. UltraSight aims to change this dynamic by offering clinicians with no prior sonography training, automated guidance and quality assessment, for conducting ultrasound scans.

UltraSight also announced the strengthening of its medical and scientific advisory board with the appointment of Al Lojewski, former General Manager Cardiology Solutions at GE Healthcare, Laurance Grossman, MD, Radiologist at Cleveland Clinic, and Andrew Cleeland, CEO of Fogarty Innovation.

“We see a future where ultrasound is readily available to assess any patient, anywhere and by any healthcare professional. Simplifying ultrasound is critical to providing fast, effective care,” said Andrew Cleeland, CEO of Fogarty Innovation. “By making ultrasound ubiquitous, UltraSight has the potential to bring the benefits of cardiac imaging to more healthcare professionals and new care settings.”

“UltraSight provides a novel and versatile platform that addresses the unmet needs of patients and physicians,” said Davidi Vortman, CEO of UltraSight. “This financing round places us on the path to become a leading player in the ultrasound industry.”

“We are excited to help realize UltraSight’s mission,” said Wonjae Lee, Head of Asia Pacific, The Yozma Group. “UltraSight’s innovation is poised to reshape the ultrasound market and propel market growth.”

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/ultrasight-raises-13-million/

Continue Reading

Medical Devices

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Avatar

Published

on

Medical Device News Magazine uses cookies to constantly improve our internet content and to create internal assessments pursuant to our data protection guidelines. We use cookies to personalize content and ads, to provide social media features, and analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.  To find out more about our cookie policy on this website, see our Privacy Policy. Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/jon-hopkins-new-senior-vice-president-chief-development-officer/

Continue Reading

Medical Devices

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Avatar

Published

on

Medical Device News Magazine uses cookies to constantly improve our internet content and to create internal assessments pursuant to our data protection guidelines. We use cookies to personalize content and ads, to provide social media features, and analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.  To find out more about our cookie policy on this website, see our Privacy Policy. Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/jon-hopkins-new-senior-vice-president-chief-development-officer/

Continue Reading
PR Newswire5 days ago

Polystyrene Foam Market worth $32.2 billion by 2026 – Exclusive Report by MarketsandMarkets™

Aviation4 days ago

What Happened To Lufthansa’s Boeing 707 Aircraft?

Blockchain4 days ago

Launch of Crypto Trading Team by Goldman Sachs

Cyber Security4 days ago

How to Become a Cryptographer: A Complete Career Guide

AR/VR5 days ago

Apple is giving a laser company that builds some of its AR tech $410 million

Aviation3 days ago

JetBlue Hits Back At Eastern Airlines On Ecuador Flights

Payments5 days ago

G20 TechSprint Initiative invites firm to tackle green finance

Cyber Security3 days ago

Cybersecurity Degrees in Massachusetts — Your Guide to Choosing a School

Cyber Security4 days ago

How To Unblock Gambling Websites?

Ripple’s XRP Price
Blockchain5 days ago

Charted: Ripple (XRP) Turns Green, Here’s Why The Bulls Could Aim $2

Blockchain3 days ago

Miten tekoälyä käytetään videopeleissä ja mitä tulevaisuudessa on odotettavissa

Aviation4 days ago

United Airlines Uses The Crisis To Diversify Latin American Network

Blockchain4 days ago

DOGE Co-founder Reveals the Reasons Behind its Price Rise

Blockchain5 days ago

South America’s Largest E-Commerce Company Adds $7.8M Worth of Bitcoin to its Balance Sheet

Blockchain5 days ago

Bitcoin Has No Existential Threats, Says Michael Saylor

Cyber Security4 days ago

U.S. and the U.K. Published Attack on IT Management Company SolarWinds

Blockchain5 days ago

Cardano (ADA) Staking Live on the US-Based Kraken Exchange

Private Equity4 days ago

This Dream Job Will Pay You to Gamble in Las Vegas on the Company’s Dime

Fintech4 days ago

The Spanish fintech Pecunpay strengthens its position as a leader in the issuance of corporate programs

Blockchain3 days ago

“Privacy is a ‘Privilege’ that Users Ought to Cherish”: Elena Nadoliksi

Trending